IVD China last week: Mindray, Wondfo, Sansure, Amoy Diagnostics, Dian Diagnostics

Mindray Animal Technology Park Officially Breaks Ground in Shenzhen

Mindray Animal Medical’s global headquarters, also called Mindray Animal Technology Park, officially broke ground in Longhua, Shenzhen. 

The Mindray Animal Technology Park spans nearly 60,000 square meters, with a building area of approximately 180,000 square meters. As the new global headquarters for Mindray Animal Healthcare, the park is set to become a world-class, comprehensive animal healthcare technology hub. It will house the global R&D center, a global customer service center, and an international academic exchange center. Its smart manufacturing base will support the production of a complete line of equipment, reagents, and consumables, including animal-specific life support, medical imaging, and in vitro diagnostic systems. An automated, digital logistics center will further bolster the park’s dynamic growth.

Wondfo Biotech Secures IVDR CE Certification for Pathology Products

Wondfo Biotech has achieved IVDR CE certification for its fully automated immunohistochemistry (IHC) staining system and secondary antibody products.  As entirely self-developed products, Wondfo’s pathology diagnostic solutions have been widely adopted and recognized both domestically and internationally due to their superior performance and high quality since their launch. 

In July 2024, Wondfo’s original PMS2 antibody (2E7-C3) also earned NordiQC Optimal certification from an internationally authoritative pathology proficiency testing organization, further validating the excellence of Wondfo’s automated IHC staining system and processes as a comprehensive solution. This IVDR CE certification reinforces Wondfo’s capacity to provide high-standard pathology diagnostic products worldwide, supporting pathologists in achieving more accurate diagnoses.

Sansure Biotech and Amoy Diagnostics Report Q3 Earnings

Sansure Biotech reported revenue of 1.033 billion CNY for the first three quarters of 2024, a year-over-year increase of 63.24%. Net income attributable to shareholders was 195 million CNY, with non-recurring net income reaching 151 million CNY, reflecting a 637.21% year-over-year increase. In Q3 alone, main revenue reached 315 million CNY, marking a 54.08% year-over-year growth.

Amoy Diagnostics posted total revenue of 848 million CNY for the first three quarters, an increase of 19.84% compared to last year, with net income attributable to shareholders at 227 million CNY, up 30.82% year-over-year. In Q3, Amoy achieved 305 million CNY in total revenue, a 22.53% year-over-year rise, and net income of 83.41 million CNY, representing a 77.58% increase from the prior year.

Dian Diagnostics Partners with Huawei Cloud for AI Health Management

On 25 October, Dian Diagnostics and Huawei Cloud officially signed an AI Health Management Cooperation Agreement at Huawei’s Zhejiang office, marking a significant step forward in their deepened collaboration in AI-driven healthcare. This partnership extends their focus from medical diagnostics to health management.

The cooperation aims to leverage Huawei Cloud’s advanced Pangu large model technology, a team of seasoned experts, and Dian Diagnostics' precise medical and diagnostic report data to further build an intelligent report interpretation platform, ultimately striving for greater efficiency and accuracy in healthcare services.